Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.
The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.
It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.
Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.
Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.
Shares of the company rose 9% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。